The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 28, 2017
Filed:
Jul. 21, 2016
Applicant:
Theravance Biopharma R&d Ip, Llc, South San Francisco, CA (US);
Inventors:
Roland Gendron, San Francisco, CA (US);
Adam D. Hughes, Half Moon Bay, CA (US);
Assignee:
THERAVANCE BIOPHARMA R&D IP, LLC, South San Francisco, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/4178 (2006.01); A61K 31/4439 (2006.01); A61K 31/506 (2006.01); C07D 413/06 (2006.01); C07D 231/14 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 403/04 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 413/04 (2006.01); C07D 231/40 (2006.01); A61K 31/454 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); A61K 31/422 (2006.01);
U.S. Cl.
CPC ...
C07D 413/06 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/4178 (2013.01); A61K 31/422 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 231/14 (2013.01); C07D 231/40 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 413/04 (2013.01);
Abstract
In one aspect, the invention relates to compounds having the formula: where R, R, R, R, and Rare as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.